Eli Lilly said a new analysis shows its GIP/GLP-1 dual agonist tirzepatide produced greater weight loss than high-dose semaglutide in adults with obesity. The number is real, and so is the caveat: it comes from an indirect comparison, not a randomized head-to-head trial.
What Happened
Lilly presented an indirect treatment comparison (ITC) at the European Association for the Study of Diabetes meeting in Milan, comparing tirzepatide, sold as Zepbound, with high-dose semaglutide, sold as Wegovy HD.
At 72 weeks, the higher of the two tirzepatide maintenance strengths was associated with 4.5 percentage points more body-weight reduction than high-dose semaglutide (95% credible interval -6.3 to -2.8). The lower strength was associated with 3.2 points more (-5.0 to -1.4). The model was adjusted for sex, age, baseline weight and baseline A1C, and used the treatment-regimen estimand - the same statistical framing used in the earlier direct trial.
The comparison extends a gap already measured directly. In SURMOUNT-5, the randomized head-to-head trial, tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide at the doses then approved, a 47% greater relative reduction, or about 50.3 pounds versus 33.1 pounds. High-dose semaglutide did not exist when that trial ran, which is precisely the gap the ITC is meant to fill.
Who Is Affected
- Clinicians choosing between two agents now that a higher semaglutide dose is available and heavily marketed.
- Patients reading headlines that present an adjusted model as if it were a trial result.
- Payers and formulary committees, who weigh relative efficacy claims when negotiating coverage.
- Gray-market buyers, for whom brand-level efficacy debates are mostly irrelevant: an unverified vial has no established dose-response at all.
Timeline
- 2025 — SURMOUNT-5 reports the first randomized head-to-head result between the two molecules.
- 2026 — High-dose semaglutide reaches the US and UK markets; Novo says it accounts for roughly 20,000 US prescriptions a week, about 5% of Wegovy volume.
- Late October 2026 — Lilly presents the indirect comparison at EASD in Milan.
- Early November 2026 — The finding circulates widely in consumer coverage.
What This Means for Researchers
Keep the evidence hierarchy straight. A randomized head-to-head trial sits above an indirect comparison, which sits above cross-trial narrative. An ITC statistically stitches together separate trials and can only be as good as the assumption that their populations, endpoints and background care are comparable. That assumption is defensible here - both programs are large and similarly designed - but it is an assumption.
Two further cautions. First, "4.5%" is percentage points of body weight, not a 4.5% relative improvement; the absolute difference is meaningful but modest against a 20% baseline. Second, both credible intervals exclude zero, so the direction is robust even if the magnitude is model-dependent. Neither result says anything about which molecule is safer, and neither substitutes for a trial in the population you actually treat.
How to Verify Your Peptides
Whatever the brand data show, an unlabeled vial has no efficacy data attached to it. Test before you rely on one:
- How peptide testing works
- HPLC versus LC-MS: what each method can and cannot prove
- Identity, purity and fill weight explained
Safe Alternatives
Read the pharmacology before the marketing:
Sources
Company research announcements (Eli Lilly, October 2026), conference presentations at EASD 2026, and peer-reviewed trial reporting for SURMOUNT-5. Effect sizes are as disclosed by the sponsor.